Why Xeris Biopharma Holdings Inc (XERS) Stock Could Be the Next Big Winner?
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
This One Factor Could Cause Xeris Biopharma Holdings Inc (XERS) Stock to Tumble
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
Xeris Biopharma Holdings Inc (XERS) Stock: Will It Continue to Fall Behind the Market?
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
Could Xeris Biopharma Holdings Inc (XERS) Stock Be on the Verge of a Decline?
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
Is Xeris Biopharma Holdings Inc (XERS) Stock’s Rally a Mirage or a Brief Lift?
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
Xeris Biopharma Holdings Inc (XERS) Stock: The One Question Investors Are Asking
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
Why Xeris Biopharma Holdings Inc (XERS) Stock Might Be Hiding a Secret Risk
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
Xeris Biopharma Holdings Inc (XERS) Stock: Is This the Calm Before the Storm?
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
Could Xeris Biopharma Holdings Inc (XERS) Stock Be in Danger of a Major Decline?
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
Xeris Biopharma Holdings Inc (XERS) Stock: Here’s Why It Might Be Time to Be Cautious
Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies […]
